Journal of Isfahan Medical School

Journal of Isfahan Medical School

Study and comparison of the efficacy and side effects of rivaroxaban and warfarin in patients with deep vein thrombosis referred to Al-Zahra Hospital.

Document Type : Original Article(s)

Authors
Narges Ansari 1
Neda Safi 2
1 Assistant Professor of Rheumatology, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
10.48305/jims.v44.i862.0745
Abstract
Introduction: Deep vein thrombosis is one of the important vascular disorders in which patients require anticoagulant drugs for a long time. Warfarin and rivaroxaban are among the common drugs for the disease, and despite their widespread use, there are disagreements about their effectiveness and side effects. Therefore, the study was conducted to compare the efficacy and side effects of rivaroxaban and warfarin in patients with deep vein thrombosis.
Methods: This prospective cohort study was conducted on 200 patients with deep vein thrombosis referred to Al-Zahra Hospital (S) in 2017-2018. Among the patients, 100 were treated with warfarin and 100 were treated with rivaroxaban. Patients were followed up for one year and the effectiveness of treatment, the incidence of side effects and drug interactions in the two groups were examined and compared.
Results: There were no significant differences between the two study groups in terms of age and gender distribution, cause of DVT, recurrence rate of DVT and drug-related complications (P<0.05). The incidence of hematuria in the warfarin group was significantly higher at 10% than in the rivaroxaban group (3%) (P=0.04). The incidence of peripheral edema in the rivaroxaban group (6%) was significantly higher than in the warfarin group (P=0.01).
Conclusion: Rivaroxaban and warfarin did not differ significantly in terms of the recurrence rate of deep vein thrombosis and the overall incidence of side effects. However, warfarin use was associated with a higher risk of hematuria and rivaroxaban use with a higher risk of peripheral edema.

Highlights

Narges Ansari: Google Scholar

Keywords
Warfarin
Rivaroxaban
Hematuria
Venous Thrombosis
Anticoagulant
Subjects
1.     Mohaddes A, Roostaee N, Abbasi Larki R, Mohammad Sadat SA. Determination of the Relative Frequency of Lower limb Deep Vein Thrombosis Risk Factors in Patients Referred to Teaching Hospitals of Yasuj, Iran, 2013 to 2014 [in Persian]. Armaghane-Danesh 2023; 28(3): 429-41.
2.     Abbasi Larki R, Roostaee N, Mohaddes A, Sadat S. Determination of the Relative Frequency of Lower limb Deep Vein Thrombosis Risk Factors in Patients Referred to Teaching Hospitals of Yasuj, Iran, 2013 to 2014 [in Persian]. Armaghane- Danesh 2023; 28(3): 429-41.
3.     Ferro JM, Canhão P. Cerebral venous sinus thrombosis: update on diagnosis and management. Curr Cardiol Rep 2014; 16(9): 523.
4.     Heil J, Miesbach W, Vogl T, Bechstein WO, Reinisch A. Deep vein thrombosis of the upper extremity: a systematic review. Dtsch Arztebl Int 2017; 114(14): 244-9.
5.     Karande GY, Hedgire SS, Sanchez Y, Baliyan V, Mishra V, Ganguli S, et al. Advanced imaging in acute and chronic deep vein thrombosis. Cardiovasc Diagn Ther 2016; 6(6): 493-507.
6.      Byrnes JR, Wolberg AS. New findings on venous thrombogenesis. Hämostaseologie 2017; 37(01): 25-35.
7.     Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12(8): 464-74.
8.     Stone J, Hangge P, Albadawi H, Wallace A, Shamoun F, Knuttien MG, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther 2017; 7(Suppl 3): S276-S284.
9.     Medina A, Raskob G, Ageno W, Cohen AT, Brekelmans MP, Chen CZ, et al. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost 2017; 117(12): 2406-14.
10.   Thaler J, Pabinger I, Ay C. Anticoagulant treatment of deep vein thrombosis and pulmonary embolism: the present state of the art. Front Cardiovasc Med 2015; 2: 30.
11.  Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005; 45(2): 127-32.
12.  Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000; 109(6): 481-8.
13.  Borsi S H, Raji H, Dargahi Malamir M, Nokhostin F, Kargaran A. Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial. Tehran Univ Med J 2021; 79(4): 281-9.
14.  Food U, Administration D. FDA expands use of Xarelto to treat, reduce recurrence of blood clots. Retrieved March 2012; 26: 2013.
15.  Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.
16.  Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358(26): 2765-75.
17.  Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372(9632): 31-9.
18.  Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363(26): 2499-510.
19.  Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17(10): 1467-507.
20.  Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor. Curr Clin Pharmacol 2014; 9(1): 75-83.
21.  Carter NJ, Plosker GL. Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Drugs 2013; 73(7): 715-39.
22.  Burness CB, Perry CM. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism. Drugs 2014; 74(2): 243-62.
23.  Abrams PJ, Emerson CR. Rivaroxaban: a novel, oral, direct factor Xa inhibitor. Pharmacotherapy 2009; 29(2): 167-81.
24.   Verma AK, Brighton TA. The direct factor Xa inhibitor rivaroxaban. Med J Aust 2009; 190(7): 379-83.
25.  Farge D, Cajfinger F, Falvo N, Berremili T, Couturaud F, Bensaoula O, et al. Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC). Oncotarget 2018; 9(43): 26990-9.
26.  Matar CF, Kahale LA, Hakoum MB, Tsolakian IG, Etxeandia‐Ikobaltzeta I, Yosuico VE, et al. Anticoagulation for perioperative thromboprophylaxis in people with cancer. Cochrane Database Syst Rev 2018; 7(7): CD009447.
27.  Investigators EP. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366(14): 1287-97.
28.  Lippi G, Mattiuzzi C, Cervellin G, Favaloro EJ. Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. Ann Transl Med 2017; 5(16): 322.
 
Journal of Isfahan Medical School
Volume 44, Issue 862
2nd Week, July
July and August 2026
Pages 745-750

  • Receive Date 15 June 2026
  • Accept Date 15 July 2026